Ⅲ期可手术乳腺癌新辅助化疗的临床疗效观察
摘要
目前,对乳腺癌的治疗手段已经成为人们的热点,经过专家的多年研究,使乳腺癌的治疗手段有了非常大的变化。本文对我院2010年4月至2012年3月的60例Ⅲ期可手术乳腺癌患者进行了新辅助化疗的临床分析,并对新辅助化疗的临床疗效进行观察研究。
出处
《中国冶金工业医学杂志》
2016年第1期75-76,共2页
Chinese Medical Journal of Metallurgical industry
参考文献2
-
1王晓稼.乳腺癌新辅助化疗的共识与争议[J].中国肿瘤,2007,16(10):788-792. 被引量：25
-
2Bonadonna G,Valagussa P,Zucal R,et al. Primary chemotherapy in espectable breast cancer[J]. CA Cancer JC lin, 1995,45 ( 4 ) : 227.
二级参考文献21
-
1Wolmark N,Wang J,Manounas E,et al.Preoperative chemotherapy in patients with operable breast cancer:nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18[J].J Natl Cancer Inst Monogr,2001,(30):96-102.
-
2Kaufmann M,Hortobagyi GN,Goldhirsch A,et al.Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer:an update[J].J Clin Oncol,2006,24(12):1940-1949.
-
3Shimizu C,Ando M,Kouno T,et al.Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer[J].Jpn J Clin Oncol,2007,37(1):1-8.
-
4Bear HD,Anderson S,Smith RE,et al.Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J].J Clin Oncol,2006,24(13):2019-2027.
-
5Trudeau M,Sinclair SE,Clemons M,et al.Neoadjuvant taxanes in the treatment of non-metastatic breast cancer:a systematic review[J].Cancer Treat Rev,2005,31 (4):283-302.
-
6Estevez LG,Gradishar WJ.Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer[J].Clin Cancer Res,2004,10(10):3249-3261.
-
7Smith IC,Heys SD,Hutcheon AW,et al.Neoadjuvant chemotherapy in breast cancer:significantly enhanced response with docetaxel[J].J Clin Oncol,2002,20(6):1456-1466.
-
8von Minckwitz G,Blohmer JU,Raab G,et al.In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer:the GEPARTRIO pilot study[J].Ann Oncol,2005,16(9):1559-1560.
-
9Buzdar AU,Ibrahim NK,Francis D,et al.Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxel,and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer[J].J Clin Oncol,2005,23(16):3676-3685.
-
10Rouzier R,Perou CM,Symmans WF,et al.Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J].Clin Cancer Res,2005,11(16):5678-5685.
共引文献24
-
1蔡媛,郑甦,冯建丽,车潇良,江奎,任转琴.乳腺癌的新辅助化疗及疗效预测因子[J].医学综述,2010,16(6):838-841. 被引量：2
-
2赵玉斌,张少华,张积仁,王金清.新辅助化疗对52例乳腺癌ER、PR和EphA2表达的影响[J].肿瘤学杂志,2010,16(3):187-190. 被引量：1
-
3赵玉斌,张少华,张积仁,王金清.新辅助化疗对乳腺癌ER、PR和EphA2表达的影响及意义[J].肿瘤防治研究,2010,37(4):457-460. 被引量：4
-
4王炳奎,窦拉加,沈国双.乳腺癌新辅助化疗的研究进展[J].社区医学杂志,2010,8(11):30-32.
-
5杨俊娥,陆苏,刘红.不同新辅助化疗方案治疗乳腺癌近期疗效观察[J].中国肿瘤临床,2011,38(7):405-408. 被引量：51
-
6Ⅱ期和ⅢA期可手术乳腺癌新辅助化疗的疗效观察[J].国际外科学杂志,2012,39(3):150-154. 被引量：8
-
7鲍新洲,金炯.TEC与CEF化学治疗方案对术后乳腺癌的疗效对比[J].中国药业,2012,21(7):46-47. 被引量：4
-
8张军华,李中,张刚,崔勇,林晓萌.复方斑蝥胶囊配合乳腺癌新辅助化疗的临床观察[J].中国肿瘤临床与康复,2012,19(2):147-149. 被引量：2
-
9匡忠生,谢宇晖,何玉萍.乳腺癌新辅助化疗疗效与ER、PR、p53及HER2表达的关系[J].中国医药指南,2012,10(25):401-403. 被引量：5
-
10雷蕾,王晓稼,杨红健,谢尚闹,孟旭莉,陈占红,许沈华.乳腺癌分子分型在新辅助化疗疗效和预后中的预测作用[J].中国肿瘤,2012,21(11):868-873. 被引量：18
-
1邱献华,王海学.新辅助化疗加手术治疗乳腺癌的临床观察[J].现代肿瘤医学,2006,14(9):1071-1073. 被引量：8
-
2袁坦,王留兴,张恒伟.新辅助化疗在Ⅲ期乳腺癌治疗中的应用[J].山东医药,2008,48(11):83-83.
-
3张晓明.Ⅲ期可手术乳腺癌新辅助化疗的近期和远期效果[J].实用癌症杂志,2004,19(3):302-303. 被引量：1
-
4周连平.新辅助化疗加手术治疗乳腺癌的疗效观察[J].中国当代医药,2012,19(19):227-228. 被引量：4
-
5刘爱军,杨朝辉,祁振国,王学智.新辅助化疗对Ⅲ期乳腺癌术后局部复发的影响[J].包头医学院学报,2006,22(2):174-175. 被引量：1
-
6黄河清,章五一,庞倩.Ⅲ期可手术乳腺癌新辅助化疗的临床疗效[J].宁夏医学杂志,2006,28(8):587-588.
-
7彭炜伟,谭介恒,黄仲杰.乳腺癌新辅助化疗的临床应用[J].齐齐哈尔医学院学报,2010,31(13):2073-2074. 被引量：6
-
8张晓明,赵安兰,张达仁,王肇炎,黄立中.Ⅲ期可手术乳腺癌新辅助化疗疗效分析[J].现代医药卫生,2002,18(4):287-287.
-
9马章春,朱宽宁.35例Ⅱ、Ⅲ期可手术乳腺癌CEF方案新辅助化疗近期疗效观察[J].社区医学杂志,2006,4(04S):18-19.
-
10钟晓捷,李高.Ⅲ期可手术乳腺癌新辅助化疗的临床疗效[J].中国热带医学,2005,5(8):1656-1657.
